Pharmaceutical

Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

Autonomix Medical, Inc. Biotech/Med Device executive Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives…

1 year ago

Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a global biotechnology company…

1 year ago

TOMI Environmental Stands Ready to Protect Public Health Amidst H5N1 Bird Flu California State Emergency

FREDERICK, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in…

1 year ago

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

FREMONT, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative…

1 year ago

Aphaia Pharma to Participate in Panel Discussion at the 1st Annual BioPharma Obesity Innovation Forum in San Francisco

ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company…

1 year ago

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and…

1 year ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Groundbreaking ‘Whole Body’ Study will be conducted by Dr. Amy Paller at Northwestern University Up to eight subjects will have…

1 year ago

Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan

Secures new $10.0 million debt facility to replace remaining $7.85 million of Avenue Capital debt Improves cash position enabling Clene…

1 year ago

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition achieved with favorable…

1 year ago

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for Libervant® (diazepam) Buccal Film in the United States…

1 year ago